May 13 - 14 Biotech & Pharma Updates

Novo Nordisk's winning streak continues, Sands Capital closes a $500M+ life science fund, and a Harvard start-up lands 3 big pharma partners.

Welcome to the TLDR Biotech newsletter!

TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you!

(You can also reach out to me on LinkedIn)

How these updates are formatted

The newsletter is split into three main sections:

  • THE GOOD - good news (eg. fundraises, product approvals)

  • THE BAD - negative news (eg. clinical trial failures, layoffs)

  • THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

  • Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

  • There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a new [Paywall] tag for any news stories behind one.

Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

⬇️ The Good News ⬇️

Approvals & Labels

CLEW Medical patient deterioration AI get’s FDA approval
Clinical surveillance, AI - Read more

Business Development

Enveric Bio out-licenses psychedelic pro-drugs to MindBio
Small molecule, psychiatry, depression, psychedelics - Read more 

Clinical Trials

Novo Nordisk’s Wegovy, persistent weight loss after 4 years
GLP-1, semaglutide, obesity - Read more

Novo Nordisk plans Wegovy studies on alcohol-related liver disease
GLP-1, semaglutide, liver disease, alcohol - Read more [Paywall]

Pliant Therapeutics announces positive topline Ph2a data
Small molecule, idiopathic pulmonary fibrosis - Read more

Novo Nordisk touts positive Ph3 hemophilia data
Bispecific antibody, hemophilia A - Read more

Earnings & Finances

Lonza bullish on CDMO future and improvements in H2 2024
CDMO - Read more

Bayer ex-USA Eylea endeavours continue growth
Eylea 2024Q1 sales: €782M ($846 million), 3.4% increase adjusting for foreign exchange rate fluctuations
Antibody fragment, macular degeneration - Read more

Allogene Therapeutics reports earnings, paints brighter future despite setbacks
Cell therapy, cancer - Read more


Sands Capital raises solid $555M life science-focused fund
Life science investing, venture capital - Read more

Apellis Pharmaceuticals secure $375M credit facility
Opthalmology, rare disease - Read more

Allozymes $15M Series A
Enzyme screening, platform technology - Read more

Brixton Biosciences $33M Series B
Pain management, osteoarthritis, drug-free - Read more 

Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

⬇️ The Good News (cont’d) ⬇️

Markets Reports

Check out the new generation of blockbuster meds - Read more


Will AI help, hinder, or replace radiologists? - Read more


Nabla Bio strikes big pharma partnership three-peat with AstraZeneca, Bristol Myers Squibb, and Takeda
Drug discovery, AI, antibody - Read more [Paywall]

FogPharma, Artbio envision a new generation of radiopharmaceuticals
Radiopharma, polypeptides, cancer - Read more

Beacon Biosignals, Longboard Pharmaceuticals epilepsy research partnership
Medical device, epilepsy, sleep - Read more

Product Launches

LG Electronics launches virtual health check-up capabilities
Virtual healthcare, remote monitoring - Read more 

⬇️ The Bad News ⬇️

Approval & Labels

Ascendis faces ascending FDA review date, 6 month extension
Hormone replacement, hypoparathyroidism - Read more

Dynavax gets rejected (label expansion) due to CRO partner mess-up
Hepatitis B vaccine - Read more


Bayer re-structuring cuts continues with 1,500 layoffs
Managerial cuts - Read more

WuXi Apptec reports “small percentage” of layoffs
CDMO - Read more [Paywall]

PacBio shutters San Diego site, lays off nearly 200 employees
Gene sequencing, equipment - Read more

⬇️ The Ugly News ⬇️


Route 92 Medical recalls catheters tied to 2 injuries and 1 death
Medical device, brain, catheters - Read more

In a similar vein, Boston Scientific launches catheter recall
Medical device, cardiac, catheters - Read more

Warning Letters, Form 483s

Not a streak you want; Eugia lands 5th Form 483 in less than a year
Sterile drug manufacturing - Read more

Not on Cue as FDA warns against Cue Health Covid-19 tests
Covid-19 tests, diagnostics, at-home testing - Read more

You’re all caught up on the latest Pharma & Biotech News!

Season 1 Nbc GIF by The Office

Gif by theoffice on Giphy

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 100+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍